Famotidin: Effect as H2 Blocker

Famotidin (brand names Pepdul, Pepcid and generics) is a selective H2 receptor antagonist and belongs to the classic acid inhibitors in gastroenterology. In Germany, famotidin is available both as a prescription drug in higher strengths and as an over-the-counter medicine in limited strength. The substance has lost importance in medical practice over the last twenty years because proton pump inhibitors (PPI) such as pantoprazole or omeprazole have stronger and longer-lasting effects. Nevertheless, famotidin continues to have a clear place, especially in patients with tolerability problems under PPI, in acute treatment of mild symptoms, and in combination therapy with other substances.

Famotidin is significantly better tolerated compared to earlier H2 blockers such as cimetidine. It inhibits CYP enzymes only minimally and therefore has a more favorable drug interaction profile. The effect occurs rapidly, making the drug attractive for acute reflux symptoms and in emergency medicine. Famotidin has a special role in oncology as adjunctive therapy in mastocytosis, carcinoid syndrome, and in outpatient reflux therapy after gastroenterological procedures.

Mechanism of Action

Famotidin competitively blocks the H2 receptor on the parietal cells of the gastric mucosa. Without the stimulating effect of histamine, the activity of the proton pump (H+ K+ ATPase) is reduced, and hydrochloric acid secretion decreases significantly. Unlike PPIs, which block the end product of the acid pump, famotidin intervenes one step earlier in the secretion pathway. This explains the faster, but somewhat less pronounced acid reduction compared to PPIs.

Famotidin inhibits both basal and meal-stimulated or stimulus-induced acid secretion. The effect begins approximately 30 to 60 minutes after oral administration, with the maximum occurring after one to three hours. The half-life is approximately three hours, and the duration of action on acid secretion is approximately 10 to 12 hours. Twice-daily or single evening dosing therapy is accordingly possible.

Oral bioavailability is approximately 40 to 50 percent. Famotidin is predominantly excreted renally in unchanged form. In renal insufficiency, the half-life increases, requiring dose adjustment. Significant hepatic metabolism does not occur, which largely excludes drug interactions via CYP enzymes.

Areas of Application

• Gastroesophageal reflux disease (GERD), especially mild cases or as supplementation to PPI for nocturnal symptoms
• Gastric and duodenal ulcers, acute therapy and recurrence prevention
• Functional dyspepsia, short-term symptomatic therapy
• Zollinger Ellison syndrome and other hypersecretory states, in higher dosages
• Stress ulcer prophylaxis in intensive care units, an alternative alongside PPI
• Mastocytosis and carcinoid syndrome, in combination with H1 antagonists
• Anaphylaxis in acute treatment, supplementary to epinephrine and H1 antagonists as adjunctive therapy

Famotidin is not first choice for severe reflux esophagitis (Los Angeles classification C or D), Helicobacter pylori eradication, or Barrett esophagus, where PPIs are the drugs of choice. Also, in recurrent ulcers without clear resolution of the cause (NSAIDs, H. pylori), acid suppression alone is usually insufficient.

Dosage and Administration

Reflux and functional dyspepsia: 20 mg twice daily or 40 mg once in the evening, typically over two to four weeks.

Ulcer therapy: 40 mg once in the evening over four to eight weeks, possibly eradication therapy for Helicobacter pylori.

Maintenance therapy: 20 mg once in the evening for recurrent symptoms, individually and after gastroenterological re-evaluation.

Zollinger Ellison syndrome: Starting with 20 mg every six hours, individual dose escalation up to 800 mg per day possible.

Over-the-counter self-medication: 10 mg for heartburn one to two times daily, for a maximum of two weeks without medical consultation.

Renal insufficiency: at eGFR below 60 ml per minute, dose reduction or extension of dosing interval. At eGFR below 30, often halving the daily dose. Hepatic insufficiency: usually no dose adjustment necessary.

Administration: with or without food, adequate water. Evening administration is particularly useful for nocturnal reflux symptoms. Those who regularly need acid inhibitors should have the underlying causes investigated by a physician.

Side Effects

Common: headache, fatigue, dizziness, constipation, diarrhea.

Occasional: nausea, dry mouth, skin rash, pruritus, temporary elevation of liver transaminases.

Rare: bradycardia, AV block with rapid intravenous administration, bronchospasm, confusion or hallucinations especially in elderly patients and renal insufficiency, thrombocytopenia, bone marrow suppression in very rare cases.

With long-term high-dose use: hypomagnesemia, vitamin B12 deficiency, increased gastrointestinal infections due to reduced gastric acid barrier. However, these effects are rarer with H2 blockers than with PPIs.

Tolerance development: with continuous use over weeks, the acid-suppressing effect may decrease somewhat (tachyphylaxis). If efficacy is insufficient, consider switching to a PPI.

Drug Interactions

• Substances with pH-dependent absorption such as itraconazole, ketoconazole, atazanavir, tyrosine kinase inhibitors (erlotinib, gefitinib, pazopanib): reduced absorption with reduced gastric acid, possibly administer therapy with time interval or choose alternative antifungals.
• Antacids: maintain two-hour interval from famotidin administration, as they may reduce famotidin absorption.
• Probenecid: inhibits renal secretion of famotidin and may increase its levels.
• Calcium carbonate in antacids: can alter famotidin absorption through increased pH.
• Other acid inhibitors such as PPIs: combination possible, clinically rarely necessary, especially supplemental in the evening.
• Glucocorticoids and NSAIDs: gastric protection possible together with famotidin, although PPIs are usually more effective with NSAID therapy.

Special Notes

Pregnancy: Famotidin is one of the better-studied H2 blockers and is considered applicable in pregnancy when clearly indicated. However, PPIs with extensive data are preferred. Breastfeeding: Minimal passage into breast milk, breastfeeding during therapy is generally possible.

Children: Use in pediatric indications possible, dosage weight-adjusted. Liquid formulations are available.

Elderly patients: consider dose reduction due to renal insufficiency and concomitant medications. Rarely, central confusion may occur.

Before starting therapy: history of Helicobacter pylori, NSAIDs, alcohol consumption, stressors, previous ulcers. Pure acid suppression without diagnosis for prolonged symptoms is not advisable because serious causes such as gastric carcinoma may be missed. With alarm symptoms (weight loss, anemia, hematemesis, melena, dysphagia, vomiting), endoscopy is mandatory.

Lifestyle: Reflux symptoms often improve through weight reduction in overweight patients, avoiding late meals, elevating the upper body at night, reduction of alcohol, coffee, and nicotine. Famotidin complements these measures, it does not replace them.

Driving ability: generally retained, individual assessment in case of dizziness or marked fatigue.

You might also be interested in

• Cimetidine, older H2 blocker with pronounced CYP inhibition
• Esomeprazole, classic proton pump inhibitor
• Sucralfate, topically acting mucosal protection
• Clopidogrel, example of acid inhibitor interactions via CYP
• Dexketoprofen, NSAID with reference to gastric protection

Frequently Asked Questions

Sources

• Gelbe Liste, Famotidin drug profile
• BfArM, Federal Institute for Drugs and Medical Devices
• AWMF, Guidelines for reflux disease and peptic ulcer disease
• German Society for Gastroenterology